You need to Sign In or Sign Up before continuing.

Emerald Health Therapeutics Inc.

lockPrivate Group

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-to-sale enterprise, Emerald has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise. Our ambition is to be at t...

people5 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200 200  png
Request Membership


Emerald Health Therapeutics Inc.

lockPrivateGroup

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-t......

people5 Members       (0)

8020 Admin posted a press release Emerald Health Therapeutics Applauds Government of Canada for Proposing Amendment to Cannabis Excise Tax in Federal Budget in Emerald Health Therapeutics Inc.

VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) applauds the Government of Canada for proposing to amend the excise tax calculation for cannabis in the federal budget announced yesterday.


The implementation of the proposed revision announced in the federal budget would result in the calculation of the excise duty of ingestible cannabis and hemp products being based on the quantity of THC in the products, as opposed to the current tax set in relation to the product volume. Certain low-THC products would also be subject to lower excise duties, which would provide additional tax relief for cannabis products typically used by individuals for medical purposes. If implemented, the proposed changes are expected to come into effect on May 1, 2019. Emerald believes that these revisions are likely to improve its profit margins on the products it intends to produce from its contracts to acquire harvested hemp. As previously announced, Emerald has entered into contracts to purchase 500 acres of harvested hemp (which contains very low levels of THC) in 2018 and up to 1000 acres of harvested hemp per annum from 2019 to 2022.


“We believe that the federal government’s recommendation to revise the cannabis excise tax will reduce taxes on the low-THC products Emerald intends to produce from its contracted hemp harvest for medical use,” stated Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We expect that this proposed revision to the excise tax calculation will enhance our opportunity to utilize our purchased hemp in an economically viable way as feedstock for new cannabinoid-containing ingestible products.”


Emerald previously announced partnerships with industry leaders in extraction and technology to enhance biological activity, its filing of patent applications, and its goal to produce value-added cannabinoid-based products that provide consumers with consistent product characteristics. Emerald has already produced various high-CBD products and management believes it is well-positioned to produce additional high-CBD, low-THC value-added products from both cannabis and hemp.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) is a Canadian licensed producer of medical and adult use cannabis. It’s Pure Sunfarms 50% joint venture owns and operates a sophisticated 1.1 million square foot greenhouse cultivating high quality, low cost cannabis in the Lower Mainland. Its wholly owned subsidiary. Verdélite Sciences Inc. is in the process of completing a 75,000 square feet indoor facility near Montreal, Quebec. Both facilities are rapidly expanding their commercial production. Emerald has also secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres per annum from 2019 to 2022 with the goal of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, and large-scale agri-business and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include augmentation of capabilities; build out of the Verdalite facility; production capacity of various facilities; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counterparties to perform contractual obligations as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!

8020 Admin posted a press release Emerald Health Therapeutics Appoints Vice President, Communications and Stakeholder Relations in Emerald Health Therapeutics Inc.

Allan Rewak brings extensive experience with government, media, communications and public affairs


VICTORIA, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Allan Rewak has been appointed Vice President, Communications and Stakeholder Relations, effective April 15, 2019.


Prior to joining Emerald, Mr. Rewak was the Executive Director at the Cannabis Council of Canada (C3), Canada’s national industry association for cannabis, cultivators and processors. In the role, he unified multiple industry associations into one collective and navigated the sector through the successful legalisation of adult-use cannabis. For his work, the Financial Post named him “One of the 20 Power Players Setting Down Roots in the Cannabis Industry”.


Mr. Rewak also served as Director of Communications and Stakeholder Relations at Newstrike Resources, a partner at Pathway Group, and a consultant at Leonard Domino & Associates.


“We are pleased to welcome Allan to the Emerald team,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “His deep industry relationships and proven experience in the sector, combined with his strong background in communications and stakeholder relations with all major relevant sectors of the industry, are expected to augment our existing capabilities.”


Mr. Rewak has been granted an option to acquire up to 150,000 common shares vesting over a three-year period.


About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include augmentation of capabilities; build out of the Verdalite facility; production capacity of various facilities; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counterparties to perform contractual obligations as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!

8020 Admin posted a press release Emerald Health Therapeutics Continues to Grow Sales with First Cannabis Shipment to Ontario Cannabis Retail Corporation in Emerald Health Therapeutics Inc.

Ontario marks a key province to offer Emerald-branded cannabis products, expanding Emerald’s market opportunity to over half of the Canadian cannabis-consuming population


VICTORIA, British Columbia, March 14, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) has fulfilled its first purchase order of cannabis from Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”).


“As we scale up production in our wholly-owned, premium indoor growing facility, Verdélite, and our large-scale, state-of-the-art joint venture greenhouse operation, Pure Sunfarms, we are consistently meeting our supply commitments of Emerald-branded adult-use cannabis in British Columbia and Newfoundland Labrador, and we are now prepared to provide the same service to the Ontario Cannabis Retail Corporation and other provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We now have distribution access to over half of the Canadian population of adult-users of non-medical cannabis. We are advancing prospective supply agreements that we expect will ultimately give us nation-wide market exposure.”


Currently, Emerald’s cannabis supply is provided primarily through its 88,000 sq. ft. Verdélite indoor facility in Saint Eustache, Quebec, and through Pure Sunfarms, its 50%-owned 1.1 million sq. ft. greenhouse facility in Delta, British Columbia. It is working to expand sources and volume of indoor, greenhouse and outdoor-grown cannabis and cannabinoid products. In 2018, Emerald acquired 500 acres of harvested hemp and expects to purchase approximately 1,000 acres of harvested hemp in 2019. It is implementing steps intended to achieve large-scale extraction and softgel encapsulation of cannabis products.


Emerald-branded products are expected to be available through the OCS next week.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC has completed the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and expects to purchase approximately 1000 acres of harvested hemp in 2019 to 2022, to provide a low-cost source of cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

10 days

8020 Admin posted a press release Emerald Health Therapeutics Sees Pure Sunfarms Licensed for 1.03 Million Square Feet of Cannabis Cultivation; Full Planting Targeted for End of April in Emerald Health Therapeutics Inc.

Pure Sunfarms’ large-scale facility with 16 grow rooms is optimized for year-round production and expected to yield more than 80 harvests annually


VICTORIA, British Columbia, March 11, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), received from Health Canada its seventh amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 206,000 square feet of growing area in the fourth and final quadrant of the greenhouse brings Pure Sunfarms’ total licensed cannabis production area to approximately 1.03 million sq. ft. in 16 grow rooms. The newly licensed area is expected to be fully planted by the end of March.


“Pure Sunfarms is now licensed across all its growing areas and we congratulate their team for this significant accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “With Emerald’s 50% stake in one of the largest fully operational cannabis production facilities in the world, we expect to realize significant economic value from Pure Sunfarms. We expect our supply agreement with Pure Sunfarms for 40% of its 2019 production, along with our Quebec and hemp operations, to support strong quarter to quarter sales growth this year.”


Pure Sunfarms is now replanting Quadrant 1 of the greenhouse following the planned suspension of production in that area last autumn to begin the process of installing supplemental lighting to maximize yields in the winter months. This project is planned to be completed in Q3, when supplemental lighting will again be required. Pure Sunfarms expects Quadrant 1 to be fully replanted by the end of April 2019, at which time Pure Sunfarms will be in production in the entire 1.03 million square feet of cultivation space.


Last week, Pure Sunfarms announced a wholesale supply agreement with Canna Farms Ltd., which will offer a select variety of Pure Sunfarms-branded high-quality dried flower products to Canna Farms’ medical clients for retail purchase. This initiative is intended to help expand the marketing and sales reach of Pure Sunfarms' branded products.  


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC has a 1.1 million square foot (25 acre) greenhouse with 1.03 million square feet of licensed cannabis cultivation space in Delta, BC. Its Verdélite operation in Québec is completing the build-out of its 88,000 square foot indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and expects to purchase approximately 1,000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include planting schedules; future sales; realization of economic value; build out of the Verdelite facility; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

14 days

8020 Admin posted a press release Emerald Health Therapeutics' Licensed Endo Product Wins Taste For Life's 2019 Essentials Supplement Award in the U.S. in Emerald Health Therapeutics Inc.

Novel Emerald endocannabinoid-supporting products well-positioned to develop brand presence and market demand among both cannabis and non-cannabis users


SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner’s, (Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For Life’s 2019 Essentials Supplement Award, which recognizes the most outstanding natural supplements in health and wellness in the U.S. Emerald will launch the Endo product line in Canada in 2019 through its joint venture, Emerald Health Naturals (“EHN”), which secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (“ECS”), but which does not contain cannabis.


Endo Bliss is part of the Endo product line of novel nutritional supplements created to support the human ECS. Formulated to promote positive outlook and mood, Endo Bliss features Emerald’s proprietary PhytoCann® Complex, an herbal and botanical complex completely free of cannabis or its derivatives. Saffron extract, which has been proven to improve mood and outlook, is also included in the formula to further bolster its efficacy.


“Endo Bliss’ recognition as a top natural supplement to support endocannabinoid health by Taste for Life in the U.S. is a notable accolade,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “The Endo product line offers people who use natural health products a completely new and unique category of nutritional supplement. To receive this award, at a time when more US retailers are showing interest in putting Endo on their shelves, is added confirmation to us that Endo is fulfilling an unmet need in the marketplace for non-cannabis products that support the endocannabinoid system.


“We aim to launch the Endo line this year via an extensive nationwide retail network of Canadian retailers that will far exceed the current number of cannabis retail stores. We will not only create a unique profit opportunity with this product line, we will create significant incremental recognition for Emerald cannabis products and an entrenched presence in natural health food, pharmacy and other channels should non-psychoactive cannabis products be permitted in these channels in the future.”


The endocannabinoid system is a biological system critical in establishing and maintaining homeostasis in every cell, tissue and organ in the body. EHB harnessed the power of non-cannabis herbs and botanicals to offer a complete nutritional line of supplements that supports the endocannabinoid system to address consumers’ most common health concerns. In addition to Endo Bliss, Emerald’s lineup includes Endo Sleep, Endo Brain, Endo Calm and Endo Inflame for rejuvenating rest, enhanced cognition, stress and anxiety support, and pain and inflammation relief.


Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.com. EHN has not announced Canadian retailers.


About Taste For Life


Taste For Life aims to educate and motivate consumers to make informed purchasing decisions. Utilizing research and insights from industry experts, the magazine covers food and special diets, vitamins, minerals, supplements, herbs, homeopathy, natural food and beauty products, recipes and other products or modalities for overall wellness.


About The Endo Product Line*


Endo Brain - Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.


Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.


Endo Calm - Naturally addresses your body’s response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.


Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.


Endo Inflame - Naturally promotes your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.


* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

29 days

8020 Admin posted a press release Emerald Health Therapeutics Launches 88,000 Square Foot State-of-the-Art, Fully-Integrated Indoor Facility and Verdélite Brand in Québec in Emerald Health Therapeutics Inc.

Verdélite is an essential element of Emerald’s commitment to develop a unique product portfolio for the large Québec marketplace and other provinces, and aims to create approximately 140 jobs in Saint-Eustache


SAINT-EUSTACHE, Québec, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced the launch of Verdélite Sciences Inc. ("Verdélite"), a wholly-owned, Québec-based production subsidiary licensed by Health Canada. Formerly known as Agro-Biotech, Verdélite currently produces high-grade dried cannabis for medical and adult-use purposes.


Emerald is nearing completion of its over $100 million investment to secure and expand its multi-purpose facility to 88,000 square feet and enable the complete cycle of indoor cultivation, product development and automated packaging of cannabis products. Upon reaching full production levels in mid-2019, Verdélite projects it will have created approximately 140 jobs.


"This investment will enable us to produce quality cannabis products adhering to our high growing and processing standards,” said Thierry Schmidt, President of Verdélite Sciences. “Verdélite will be synonymous with differentiated and value-added cannabis products, and we are pleased to see the level of industry skill and enthusiasm coming from the Saint-Eustache community and the local interest and support to help contribute to our success.”


In addition to 23 state-of-the-art growing rooms, the facility will include an analytical testing laboratory as well as a research centre for product innovation and extraction technology. These capabilities will also position Verdélite to competitively participate in the development and production of edible cannabis products, which are expected to be sanctioned by Health Canada by October 17, 2019.


"We’re delighted to see our Québec-based Saint-Eustache facility coming online and adding to our capability to deliver high quality adult-use and medical cannabis products,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “The Verdélite team has been working tirelessly to bring to fruition one of the core assets in Emerald’s national and international development strategy.”


Emerald acquired Verdélite in May 2018 with an operating footprint of 25,000 square feet. The full 88,000 square foot facility is expected to be operational in Q2 2019, with approximately 50,000 square feet of cannabis flowering capacity in precision-controlled environments. Verdélite possesses approximately 200 strains of cannabis.


By the Numbers



  • 140 estimated full-time jobs in Saint-Eustache once fully operational

  • 88,000 square foot purpose-built cannabis production facility

  • 23 independent growing rooms

  • 200 cannabis strains

  • 12 processing and packaging rooms.


About Verdélite Sciences Inc.

Verdélite, a wholly owned subsidiary of Emerald Health Therapeutics, Inc., is a Health Canada- licensed cannabis cultivation facility located in Saint-Eustache, 30 km north of Montréal, Québec. This facility, purpose-built to produce, process and package cannabis products, is nearing completion of an expansion to 88,000 square feet. The facility has abundant access to high-quality low-cost water and electricity.


About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acres) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 88,000-square-foot indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres from 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agribusiness, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceuticals, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Verdélite/Emerald Investor and Public Relations
Marie-Eve Chaume
+1 514 951-5498
mechaume@Verdélite.ca


Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include projected job creation figures at our operating facilities; production and processing capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Announces Completion of Pure Sunfarms CAD$20 Million Credit Facility with Bank of Montreal and Farm Credit Canada in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.


“Pure Sunfarms is proud to enter into this Credit Facility with these two highly respected institutional lenders,” said Mandesh Dosanjh, President and Chief Executive Officer, Pure Sunfarms. “This is truly an exciting time for our organization and we are appreciative of the support of each as Pure Sunfarms establishes itself as a vertically integrated supplier to the Canadian cannabis market.”


“As Pure Sunfarms approaches operational positive cash flow, completion of a non-dilutive financing with these financial institutions is an excellent accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We look forward to Pure Sunfarms’ rapid quarterly growth through this year as it comes fully onstream.”


The Credit Facility, which matures on February 7, 2022, is secured by Pure Sunfarms’ greenhouse facility, and contains customary financial and restrictive covenants.


With conversion of all growing areas, totaling more than one million square feet, of its greenhouse facility completed, Pure Sunfarms expects to be in production in all quadrants of the facility in the first quarter of this year. The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms optimized for year-round harvesting (more than 80 harvests annually).


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


 

!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Announces Pure Sunfarms' Selection to Supply Ontario Cannabis Store in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.


“Pure Sunfarms’ supply agreement with the OCS – our first with a provincial government distributor – is a tremendous step forward for our organization, putting our branded quality products on the OCS website and soon retailers’ store shelves, and into the hands of our consumers,” said Mandesh Dosanjh, President and Chief Executive Officer, Pure Sunfarms. “The confidence of the OCS in Pure Sunfarms’ ability to reliably supply safe, consistent quality products is a testament to the hard work of the entire Pure Sunfarms team, which has been relentless in advancing our organization to this stage. We are thrilled to be working with the OCS in Canada’s most populated province and look forward to finalizing additional supplier agreements for other provinces and growing the Pure Sunfarms brand nationally.”


“Pure Sunfarms’ progress in building out an eminent cannabis growing facility, which provides a natural progression into retail sales and product development for the growing and evolving cannabis marketplace, as well as its accomplishment in winning its first provincial government supply agreement is a great validation of the broader business strategy. I applaud CEO Mandesh Dosanjh and the Pure Sunfarms team,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “With cannabis supply we have secured from Pure Sunfarms, our Verdélite operation, and other sources, Emerald has been supplying British Columbia and Newfoundland/Labrador under existing supply agreements and expects to imminently ship to Ontario under the supply agreement it announced last fall. The Pure Sunfarms operation is poised for significant value generation and is a vital part of Emerald’s portfolio.”


With this Ontario supply agreement in place, Pure Sunfarms can commence shipments to the OCS upon receipt of its packaging and processing licenses from Health Canada, which it continues to expect in the near term, subject to Health Canada’s own timelines.


Pure Sunfarms has been and continues to pursue additional supply agreements with other provincial government distributors and private retailers as it continues to sell directly to other Licensed Producers to capitalize on favorable spot market pricing amidst the continuing cannabis supply shortage across Canada.


Pure Sunfarms recently completed conversion of all of the growing area – more than 1 million square feet – at its 1.1 million square foot greenhouse in Delta, British Columbia, making it one of the largest single cannabis growing facilities in the world. The first three quadrants of this facility are licensed for cultivation, with the fourth quadrant currently under Health Canada licensing review. Pure Sunfarms expects to be in production in all four quadrants of this facility in the first quarter of 2019.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Secures Proprietary Extraction Technology and Extraction Capabilities in Agreement with Indena in Emerald Health Therapeutics Inc.

Emerald receives certain exclusive rights to established Phytosome® technology to enhance absorption and bioavailability of cannabinoid products

Leading global extraction researcher and manufacturer to provide license of technology and global industrial-scale manufacturing of non-psychotropic cannabinoids for food and health use in Canada

VICTORIA, British Columbia, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.


This collaboration leverages Indena’s decades-long global presence in the plant extraction industry and botanical experience in phytochemical research. Indena is the world’s leading company in the identification, development, and production of plant-derived active ingredients for the pharmaceutical, health food, and personal care industries. It is adapting an existing proprietary extraction process to facilitate hemp extraction and will exclusively provide Emerald in Canada with this highly optimized process for extracting and isolating CBD to manufacture cannabinoid-based products. With multiple international large-scale extraction facilities, Indena will be the exclusive  third party manufacturing supplier of CBD for Emerald. Emerald will use this CBD in its production of certain product lines.


Emerald and Indena have also established a research collaboration to assess the use of Indena’s Phytosome® technology in combination with various cannabinoids. The agreement provides Emerald with exclusive access to certain of Indena’s scientifically validated, commercially available Phytosome® formulations and plant-based technology that is designed to enhance solubility of compounds that are usually poorly absorbed by the body, such as cannabinoids.  For Emerald, evaluating and securing superior technologies like Phytosome® is an important aspect of its objective to develop differentiated and effective cannabinoid-based products to improve human health.


“Emerald is one of the few Licensed Producers in Canada focused on applying proprietary  innovation to improve the medical applications of cannabinoids, which is fully aligned with Indena’s scientific approach to phytochemical research,” said Stefano Togni, Business Development and Licensing Director of Indena. “We believe that both companies’ approaches to quality and innovation will create an exciting partnership that will add value to the industry and better serve patients and consumers who look for excellence in their products and predictive health outcomes.”


“In my many years as a practicing naturopathic physician, Indena has been the gold standard in plant extraction in the natural health products industry,” said Dr. Gaetano Morello, Chair of Emerald’s scientific advisory board and CEO of Emerald Health Naturals. “By gaining access to their technology, know-how, and expertise, Emerald is propelling itself as a leader in the innovation of next generation CBD-based products.”  


“Reinventing processes and replicating existing expertise does not make sense to us when we can work with the best. We welcome Indena’s decision to work closely with our team,” added Dr. Avtar Dhillon, President and Executive Chairman of Emerald Health Therapeutics. “We aim to bring together unbeatable global expertise, technology and infrastructure to innovate and commercialize value-added cannabinoid-based products, and we will do this with both internal resources and industry-leading partners.


“Indena is one of the oldest and most established extraction businesses in the world. They have served international pharmaceutical companies with natural anti-cancer ingredients. They are leaders in nutraceutical products. With multiple extraction-related deals announced, our comprehensive and cohesive international strategy for cannabis and hemp extraction is unfolding. We look forward to impactful cannabinoid product development advancements in 2019.”


About Indena


Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants for use in the pharmaceutical, health food and personal care industries. Backed up by almost a century of botanical experience, the company holds more than 120 primary patents, has published more than 700 scientific studies and co-operates with the world’s most prestigious universities and private research institutions. Indena employs about 800 staff, investing around 10% of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has 5 production sites and 5 international branches throughout the world and manages sales in more than 70 countries. The Company’s experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMA, FDA and ESCOP, and cooperate on the update of all the main pharmacopoeias. Today, Indena also supplies capacity and expertise for custom manufacturing services and related key technologies. In particular, the company has expanded its offering with a new kilolab to handle semisynthetic and totally synthetic active pharmaceutical ingredients (API) that require high containment, ie. occupational exposure limit (OEL) of 20 μg/m3.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries. 


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Discharge of Litigation in Emerald Health Therapeutics Inc.

VANCOUVER, British Columbia, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.


Pursuant to the settlement, all claims against Verdélite have been discharged without Verdélite making any payment or providing any compensation to Pivot.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; increased commercial production; implementation of future business plans; intellectual property and product development; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics' Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US in Emerald Health Therapeutics Inc.

Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada


VICTORIA, British Columbia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019.  The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.


In December 2018, EHT received natural product numbers (NPNs) from Health Canada to sell Endo in Canada. EHN is owned 51% by Emerald and 49% by EHB.


“For the Endo products to be embraced by retailers with such high standards of retail excellence and broad reach like Whole Foods Market in the US is an important milestone for this unique natural health supplement line,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “A non-cannabis product line capable of nurturing the endocannabinoid system is a unique product category - and it is one that is garnering significant attention in the US. We aim to similarly build strong distribution channels with top retailers in Canada in 2019.”


“With 60% of cannabis users also being users of natural health products, we have a two-pronged opportunity in Canada to build a stand-alone market for the Endo product line for cannabis non-users as well as achieve Emerald brand recognition among cannabis users in channels unable to carry cannabis products,” said Avtar Dhillon, President and Executive Chairman, Emerald Health Therapeutics. “Natural health product stores, pharmacies, and even grocery stores may all be potential outlets for the Endo product line. We look forward to offering the proprietary Endo products to Canadian consumers this year.”


Endo nutritional supplements feature PhytoCann-Complex™, a proprietary formulation consisting of non-cannabis, non-psychoactive, plant-based bioactive compounds that support the body’s endocannabinoid system. The role of the ECS as the body’s innate balancing mechanism is key to the regulation of everything from appetite, energy, metabolism, fertility and immunity to sleep, mood, pain perception and memory.  The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss and Endo Inflame, and they are intended to naturally address the body’s response to conditions such as stress, anxiety, restless sleep and pain, and foster overall health and wellness.


Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.com.


About The Endo Product Line*

Endo Brain -
Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.


Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.


Endo Calm - Naturally address your body’s response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.


Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.

Endo Inflame - Naturally promote your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.

* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health sees Expansion of Pure Sunfarms' Cannabis Cultivation License to 825,000 Square Feet in Emerald Health Therapeutics Inc.

1.1 million square foot Pure Sunfarms facility on track to reach full production capacity in first half 2019


VICTORIA, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.


Pure Sunfarms has also completed conversion of the approximately 206,000 square feet of growing area in the fourth and final quadrant, which is under review by Health Canada with respect to further amendment of Pure Sunfarms’ cultivation license. This further amendment would expand its permitted production area to just over 1.03 million square feet. The remaining approximately 69,000 square feet of the facility is being converted to processing and extraction activities. The Pure Sunfarms Delta greenhouse will be one of the single largest cannabis growing facilities in the world.


“With deep cannabis and large-scale greenhouse growing expertise, established operational systems, and cannabis strains well-suited to a greenhouse environment, we expect Pure Sunfarms’ leadership in optimized greenhouse cannabis growing to achieve attractive quality, yield, and profitability,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “We expect this facility to be in full production in the first half of 2019. With Emerald’s supply agreement for 40% of Pure Sunfarms’ 2019 production along with our Quebec and hemp operations, we are strongly positioned for quarter to quarter sales growth.”


All supplemental lighting is operational in Quadrants 2 and 3 of the Pure Sunfarms facility, and is expected to be operational in Quadrant 4 upon start of production, supporting maximum yields during the lower daylight winter months. Supplemental lighting infrastructure is currently being installed in Quadrant 1 and will be completed prior to Quadrant 1 resuming production in late February 2019. Conversion of Quadrant 1 was completed in April 2018 without supplemental lighting to enable immediate production during the summer when supplemental lighting was not needed.


The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms (13 of which are now licensed) optimized for year-round harvesting (more than 80 harvests annually).


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Secondary Offering in Emerald Health Therapeutics Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.


The Selling Shareholder will receive all of the net proceeds from the Secondary Offering. No securities are being sold by the Company.


In connection with the Secondary Offering, the Company has agreed to file a shelf prospectus supplement qualifying the Secondary Shares for distribution in each of the provinces of Canada, except Quebec, in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.


The closing date of the Secondary Offering is expected to be on or about January 16, 2019, and is subject to customary closing conditions.


This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite (previously called Agro-Biotech) operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include statements relating to the filing and effectiveness of the prospectus supplement; the anticipated closing date of the Secondary Offering; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to meet the conditions of closing of the Secondary Offering; filing of the shelf prospectus supplement; uncertainty with respect to the completion of the Secondary Offering; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Joint venture to distribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).


Emerald has invested $5,000,000 for 51% equity ownership of EHN. EHB has granted EHN the exclusive Canadian distribution rights to EHB’s award-winning product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.


Market research commissioned by the Company identified that approximately 60% of legal cannabis users also use natural health products. This strong consumer overlap between the two markets is expected to create a unique opportunity for Emerald to build its health brand through EHN and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not authorized to sell cannabis under the Canadian federal cannabis regulations for recreational use which came into force on October 17, 2018. However, if these channels are approved in the future, the Company expects to be well positioned to introduce its cannabis-based products into these channels.


The formation of the Joint Venture is a “related-party transaction” as such term is defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as EHB is approximately 71% owned by Emerald Health Sciences Inc., which is also the holder of approximately 30.6% of the outstanding common shares of the Company. The Company is relying on the exemption from the formal valuation requirements of MI 61-101 set out in Section 5.5(b) of MI 61-101 and the exemption from the minority shareholder approval requirements of MI 61-101 set out in Section 5.7(a) of MI 61-101 in respect to the creation of the Joint Venture.


In connection with the formation of the Joint Venture, EHN has also acquired the assets of GAB Innovations (“GAB”) and has granted non-exclusive sub-distribution rights to Avricore Pharmaceuticals Inc. (formerly VANC Pharmaceuticals Inc.) (“Avricore”). Both GAB and Avricore have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.


Emerald also announces that Chris Wagner has resigned as a director of the Company. As previously announced, Mr. Wagner stepped down as CEO effective November 28, 2018. Mr. Wagner will continue to act as a consultant to Emerald and provide assistance when needed.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include the operations of the joint venture; establishment of brands; sale of products; regulation of the cannabis industry; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

3 months

8020 Admin posted a press release Weather Telematics Inc. to Exhibit at CES 2019 in Las Vegas in Emerald Health Therapeutics Inc.

TORONTO and OTTAWA, Ontario, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE: ITT; OTC: INOTF; FRANKFURT: 71T) (“IoT Inc.” or the “Company”) a strategic investor and operator of emerging technology companies with innovative IoT, AI and Blockchain solutions, is pleased to announce that its wholly-owned subsidiary, Weather Telematics Inc. (“WTX Inc.” or “Weather Telematics”) will be showcasing its innovative road safety data and smart mobility technology at the Consumer Electronics Show 2019 (“CES”) in Las Vegas from January 8th – 11th in the Canadian Delegation Booth (#1021, Tech East, Westgate).


Attendees that visit the booth will have the opportunity to interact with the Weather Telematics’ dynamic platform that mitigates weather risk, reduces traffic congestion and makes connected and autonomous navigation safer in all types of road conditions. Throughout the conference, Weather Telematics will be hosting a technology presentation at its booth focused on its smart mobility solutions for autonomous driving and connected vehicles.


From tech powerhouses to innovative start-ups, companies big and small from all industries come to CES to introduce the latest innovation to the global market. Exhibitors feature products from all facets of tech, including sports and vehicle technology, artificial intelligence, drones, augmented and virtual reality, smart cities and resiliency, digital health and more. Manufacturers, developers and suppliers gather at CES to not only showcase game-changing technology to the world, but to also build strong business relationships with new and existing industries.


“Our roots lie in designing and deploying the largest meteorologically approved mobile weather observation platform in North America. Since 2010, this network has delivered millions of observations daily to the National Weather Service allowing for delivery of dynamic road weather conditions across the USA,” says Michael Keefe, Chief Strategy Officer at Weather Telematics. “We are honoured to be selected as one of the leading information and communications technologies companies within Canada and to be featured within the Canadian Delegation booth at CES.”


For OEMs, suppliers and tech companies in the smart mobility space wishing to learn more about partnering with Weather Telematics and discussing integration opportunities for Weather Telematics’ software and sensors into their products or technologies, visit www.weathertelematics.com or visit the booth during CES to schedule a private meeting.


About Weather Telematics Inc.
Founded in 2010, Weather Telematics Inc. is a Canadian-based, IoT data science company offering road safety data products for industrial, government and consumer markets. Weather Telematics uses a proprietary vehicle-mounted mobile IoT sensor network and AI machine learning system to generate real-time and predictive road weather conditions, road hazard risk alert notifications and dynamic routing applications. The Weather Telematics platform mitigates weather risk, reduces traffic congestion and makes connected and autonomous navigation safer in all types of road conditions.


To learn more, visit: www.weathertelematics.com
Follow Weather Telematics on Twitter: https://twitter.com/weathertx


About Internet of Things Inc.
Internet of Things Inc. is a strategic investor and operator of emerging technology companies with innovative technology solutions. The Company creates value through its portfolio companies’ expertise in IoT, AI and Blockchain solutions, by turning data into actionable intelligence to drive more efficiency into organizations.

The Company owns Weather Telematics Inc., has a joint venture partnership, New Hope IoT Intl Inc., with New Hope Data Technology Co. Ltd., and has its headquarters in Toronto, Canada. 

Follow Internet of Things Inc. on:

















Facebook: https://www.facebook.com/InternetofThingsInc/
Twitter: https://twitter.com/iotintl
LinkedIn: https://www.linkedin.com/company/internet-of-things-inc-

For further information, contact:


Internet of Things Inc. 
Kim Nguyen, Director of Corporate Communications
Mobile: (647) 201-7993
Email: knguyen@iotintl.com
To learn more, visit: www.iotintl.com


Weather Telematics Inc.
Michael Keefe, Chief Strategy Officer
Mobile: (416) 580-6559
Email: mkeefe@weathertelematics.com
To learn more, visit: www.weathertelematics.com


Cautionary and Forward-Looking Statements
Statements contained in this news release, which are not historical facts, are forward-looking statements that involve risk, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements included in this news release are based on information available to the Company on the date hereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results of the Company to differ materially from the conclusion, forecast or projection stated in such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to factors referenced in the Company’s other continuous disclosure filings, which are available at sedar.com. Readers should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statements, except as required by applicable securities laws.


NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

!
Thumb 8020 monitor 200 200  png

8020 Admin

3 months

8020 Admin posted a press release Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada in Emerald Health Therapeutics Inc.

1.1 million square foot Pure Sunfarms facility steadily ramps capacity and production with industry-leading quality and yields in line with expectations


VICTORIA, British Columbia, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.


“Pure Sunfarms is already one of the largest licensed cannabis production facilities in the industry, and we expect completion of the conversion in Q1,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “With deep cannabis and large-scale greenhouse-growing expertise, established operational systems, and multiple cannabis strains being grown, Pure Sunfarms is achieving industry-leading quality and yields in line with our expectations. We expect this facility to be in full production in the first half of 2019, and aim for it to be one of the best cannabis production operations in the industry.


“Pure Sunfarms has delivered to Emerald contracted cannabis shipments that we are selling under the Emerald brand. It is also selling to other LPs, with favourable spot market pricing, as it awaits its packaging sales license to commence direct sales to provincial distributors. Pure Sunfarms continues to implement its plan to be a vertically integrated cannabis producer and marketer.”


Pure Sunfarms has completed conversion of the remainder of Quadrant 3 and is awaiting Health Canada approval for this additional approximately 138,000 square feet of production area. Pure Sunfarms expects to complete conversion of Quadrant 4 (approximately 275,000 square feet) by year end and anticipates Health Canada approval of that additional area by the end of January 2019. At a total licensed area of 1.1 million square feet, Pure Sunfarms’ Delta greenhouse will be one of the single largest cannabis growing facilities in the world.


All supplemental lighting is operational in Quadrants 2 and 3, and is expected to be operational in Quadrant 4 upon start of production, supporting maximum yields during the lower-daylight winter months. Supplemental lighting will be installed in Quadrant 1, which was completed as per plan earlier this year without supplemental lighting in order to permit immediate production during the summer months when supplemental lighting is not required. Quadrant 1 is expected to resume production by the end of February 2019.


The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms (eleven now licensed) optimized for year-round harvesting with more than 80 harvests annually.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


 


!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System in Emerald Health Therapeutics Inc.

Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health

Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product line

VICTORIA, British Columbia, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. ("Emerald" or “the Company”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients. EHN intends to launch the Endo product line over-the-counter in Canadian natural health product, grocery, and pharmacy stores by mid-2019.


“Our Endo product line was developed by internationally recognized natural health product experts and is unique in the natural healthcare marketplace. We are very excited to be able to offer our Endo products to Canadian consumers to support their endocannabinoid systems and improve aspects of their health,” said Dr. Gaetano Morello, CEO of EHN. “We are leveraging our key strategic relationships and working hard on the marketing, manufacturing and logistical steps in order to launch the Endo line by mid-2019.”


The Endo product line was developed by Emerald’s joint venture partner, San Diego-based Emerald Health Bioceuticals, Inc. (“EHB”), and its scientific advisors. Over the last year, EHB has secured multiple distribution and sales channels in the United States and internationally for the Endo product line, ranging from small independent natural health product retailers to nation-wide grocery store chains and Amazon.com. EHN, which is owned 51% by Emerald and 49% by EHB, will have exclusive Canadian distribution rights to the Endo products.


These cannabis-free nutritional supplements feature PhytoCann-Complex™, a proprietary formulation designed to support the body’s endocannabinoid system, which plays a central role in the orchestration, maintenance, and balance of health and well-being. The products include Endo SleepTM, Endo InflameTM, Endo BrainTM, Endo BlissTM, and Endo CalmTM. Endo Brain was recently awarded a prestigious 2018 SupplySide Consumer Packaged Goods Editor’s Choice Award for Brain Health, building on its NEXTY "Editor's Choice" Best New Supplement Award in the natural products industry in 2017.


“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “In the event that CBD and other non-psychoactive cannabinoid products are allowed to be sold in these channels in the future, Emerald will be well positioned to add its cannabinoid compounds to the Endo product line and leverage its early marketing advantage. Emerald’s vision is to enhance human health through cannabis science. The creation of EHN and the launch of the Endo product line in Canada are key steps in Emerald’s strategy to achieve this goal.”


As announced in the Company’s press release dated November 22, 2018, the Company has obtained conditional approval of the TSX Venture Exchange for the formation of the EHN joint venture. The parties are in the process of finalizing definitive documentation with respect to EHN. Formation of EHN is conditional upon final regulatory approval and settlement of definitive documentation.


About the Endocannabinoid System


The endocannabinoid system (“ECS”) is a biological system with a vital role in regulating human health and disease. A lack of balance in the endocannabinoid system is likely to have adverse consequences in a number of human health conditions. The ECS is activated by endocannabinoids produced naturally in the body, but also by cannabis or non-cannabis plant ingredients that mimic the actions of cannabinoids produced in the body. All products in the Endo product line contain Phyto-CannTM Complex, which has been formulated by leading nutritional and cannabinoid scientists with non-cannabis herbal and botanical cannabinoids designed to favorably impact the ECS.


About Emerald Health Therapeutics


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acres) greenhouse in the Lower Mainland to cultivate cannabis and its Agro-Biotech operation in Québec is currently operating out of its 75,000 square feet indoor cannabis cultivation facility. Commercial production is expanding in both facilities. In addition, Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol out of its hemp harvest. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald, EHN and EHB are all part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law. 

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale in Emerald Health Therapeutics Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VICTORIA, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.


The Company intends to use the net proceeds of the Offering to fund the completion of capital projects, research and development, working capital, and general corporate purposes.


The Common Shares will be qualified under a shelf prospectus supplement to be filed by Emerald in each of the provinces of Canada, except Quebec, prior to closing in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.


The closing date of the Offering is expected to be on or about December 7, 2018, and is subject to certain conditions including, but not limited to, the Lead Investor being satisfied with the results of its due diligence, no material adverse change in the affairs of the Company, and the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.


This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include statements relating to the filing and effectiveness of the prospectus supplement; the use of proceeds from the Offering; the anticipated closing date of the Offering; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to meet the conditions of closing of the Offering; uncertainty with respect to the completion of the Offering; filing of the shelf prospectus supplement; the ability to obtain applicable regulatory approval for the Offering; failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin posted an update in EMERALD HEALTH THERAPEUTICS INC.

4 months

Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update

https://quotemedia.com/portal/quote/?qm_symbol=EMH%3ACC

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO.


“Emerald’s board of directors thanks Chris for his numerous contributions during this period of rapid growth and wishes him well in his future endeavours,” said Jim Heppell, a director of Emerald. “Emerald has now laid the groundwork for very rapid future growth. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations. Under his experienced stewardship, we expect Emerald to rapidly advance its differentiated business plan.”


Dr. Avtar Dhillon said, “Our plan is to build on the momentum of, and accelerate, our foray into the world cannabis arena and leverage our asset base to maximize our opportunities not only in Canada, but globally.  Our goal is to be a preeminent player on the global stage, with science-backed innovative cannabinoid products. As such, we are finalizing our expansive relationship with the Factors Group, which, when complete, is expected to provide industrial-scale extraction, encapsulation, packaging, and distribution capability. We intend to feed this processing capability with supply from our Pure Sunfarms joint venture, our Quebec facility, and hemp to be obtained through our supply agreement.”


Dr. Dhillon is a life sciences entrepreneur with more than 35 years of experience. He is CEO of Emerald Health Sciences, a major shareholder of the Company, and serves as a board member and chairman of several life science companies. He is also Chairman of the Cannabis Canada Council. As a founder/co-founder of many life science companies, he has raised more than $1B in public and private financings. As President and CEO of Inovio Pharmaceuticals, Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.). Prior to his business career, Dr. Dhillon practiced family medicine. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.


Emerald would also like to announce the departure of Paul Dillman as Executive Vice President of Global Sales and Marketing of the Company, effective as of November 22, 2018.  The board also thanks Mr. Dillman for his service.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; completion of the strategic relationship with Factors Group; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Appoints Agro-Biotech President in Emerald Health Therapeutics Inc.

Thierry Schmidt brings extensive marketing and business strategy experience from consumer goods industry



VICTORIA, British Columbia, Nov. 22, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been appointed President of Agro-Biotech, its Québec-based licensed cannabis production operation, effective November 26, 2018. Mr. Schmidt brings 20 years of experience in marketing, brand advocacy, and general management; he has held senior leadership positions at Next Level Energy Inc., L’Oréal Canada, and British American Tobacco.


“We welcome Thierry to Agro-Biotech. As a born-and-raised Francophone with deep consumer goods business and marketing expertise, Thierry is ideally positioned to advance Agro-Biotech’s strategy to serve patients and consumers in Quebec,” said Mr. Chris Wagner, CEO, Emerald Health Therapeutics.


“Agro-Biotech and Emerald stand out in the cannabis industry for their extensive experience in life sciences as well as cannabis cultivation and marketing,” said Mr. Schmidt. “I look forward to driving a highly competitive production and product strategy for Agro-Biotech.”


Mr. Schmidt is a seasoned marketing executive leader with extensive experience in the consumer goods industry. He has held leadership and senior management positions in new business development, operations, sales, investor relations, and brand/consumer development. As General Manager at L’Oréal and Chief Marketing Officer at Next Level Energy Inc., he managed product development focused on developing a sustainable and profitable business model as well as brand advocacy. Furthermore, in his Business Development and Sales Director roles at British American Tobacco, he successfully developed and launched a national trade marketing strategy. 


Mr. Schmidt has been granted an option to acquire up to 125,000 common shares vesting over three years.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. It secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; implementation of business strategies; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture in Emerald Health Therapeutics Inc.

Joint venture to distribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies


VICTORIA, British Columbia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”).


The Company will invest $5,000,000 for 51% equity ownership of EHN. EHB will grant EHN the exclusive Canadian distribution rights to EHB’s award-winning product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements, which use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.


Market research commissioned by the Company identified that approximately 60% of legal cannabis users also use natural health products. This strong consumer overlap between the two markets creates a unique opportunity for the Company to establish its health brand through EHN and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not authorized to sell cannabis under the Canadian federal cannabis regulations for recreational use which came into force on October 17, 2018. However, if these channels are approved in the future, the Company expects to be well positioned to introduce its cannabis-based products into these channels.


The formation of the Joint Venture is a “related-party transaction” as such term is defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as EHB is approximately 71% owned by Emerald Health Sciences Inc., which is also the holder of 32% of the outstanding common shares of the Company. The Company is relying on the exemption from the formal valuation requirements of MI 61-101 set out in Section 5.5(b) of MI 61-101 and the exemption from the minority shareholder approval requirements of MI 61-101 set out in Section 5.7(a) of MI 61-101 in respect to the creation of the Joint Venture.


The parties are in the process of finalizing definitive documentation with respect to the Joint Venture. Formation of the Joint Venture is conditional upon final regulatory approval and settlement of the definitive documentation.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include final closing of the joint venture; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments in Emerald Health Therapeutics Inc.

Emerald delivers first shipments to British Columbia and Newfoundland and Labrador


VICTORIA, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.


“It has always been important to us to ensure we fulfill the supply commitments we made to our provincial cannabis distribution customers. We are pleased that our initial deliveries have met this obligation and that we have the ability to provide consistent and increasing contracted shipments of Emerald products,” said Paul Dillman, Emerald’s Executive VP, Global Sales & Marketing. “With proprietary market research, differentiated products based on unique plant genetics, a recognizable, trusted brand, significant marketing expertise and bandwidth, and a growing sales team across Canada, we are aiming for a significant ramp-up in sales every quarter from these initial deliveries forward.”


“Emerald aims to assure its customers a secure supply of an array of products by establishing significant, diverse sources of indoor, greenhouse, and outdoor-grown cannabis and cannabinoid products. We have a strong and building foundation to achieve this goal,” said Chris Wagner, CEO at Emerald. “Our products are now available in stores and online in BC as well as Newfoundland and Labrador. Emerald is in negotiations with cannabis distribution authorities in several provinces as we continue to scale our production and sourcing efforts.”


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Portions of both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include ramping up production and sourcing of cannabis and cannabinoid products; future deliveries of Emerald products; availability of Emerald products in other provinces; production capacity of various facilities; expansion of facilities; anticipated production costs; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose(TM) Cannabis Products in Emerald Health Therapeutics Inc.

Unique Emerald cannabinoid formulations and dosage forms focused on providing consumers precise and differentiated products based on protected intellectual property


VICTORIA, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose™ cannabis products will, when made available to the public, provide consumers with products currently not available.


The seventeen Defined Dose™ cannabis patent applications relate to:



  • Inhaled dosage forms for smoking

  • Inhaled dosage forms for vaping; and

  • Capsule and edible formulations and dosage forms based on a novel understanding of cannabinoid molecular pathways and how they influence disease mechanisms.


Certain of the Defined Dose™ cannabis products are eligible for launch in Canada under existing Canadian regulations. Others are expected to be eligible under anticipated regulatory changes in 2019.


“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald’s filing of these patent applications is an important step,” said Chris Wagner, CEO of Emerald. “Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechologies Espana.”


“Emerald’s intent is to be at the forefront of understanding the mechanism of action of the endocannabinoid system and developing proprietary products that enable both medical and adult-use consumers to achieve measured outcomes with well characterized, reliable products,” said Avtar Dhillion MD, Executive Chairman of Emerald. “Our aim is to produce a product pipeline of next-wave cannabis products that fit the better-defined needs and preferences of consumers as Canada and other countries that legalize medical and recreational cannabis use.”


Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most important "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 member countries worldwide over the coming year.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Its 50%-owned Pure Sunfarms in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis in Canada and other countries; eligibility of products for launch in Canada; availability of products to the public; regulatory changes; potential for market growth; safety enhancement; expansion of research and development; future product development; future filings for patent protection; acceptance of filings; grant of patent rights; production capacity of various facilities; and expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals, including approval of patent filings; efficacy of safety features; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. Mr. Dillman previously served as Vice President of Sales and Marketing, and will now be responsible for leading international marketing, sales, and customer services for Emerald as the company prepares to participate in the new legal cannabis landscape.  


“Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald. “With our branding, marketing and sales strategy, Emerald is poised to be a premiere provider of cannabis for medical and adult-use consumers. Paul’s marketing expertise has been invaluable to our team over the past few months, and we look forward to positioning Emerald to be a leader in Canada as well as the global cannabis industry.”


Mr. Dillman has three decades of experience in global marketing, sales, and general management and prior to Emerald, held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods. Mr. Dillman earned a bachelor of science from West Point (United States Military Academy) and a master of science in systems management from the University of Southern California.


The Company has granted 50,000 stock options to Mr. Dillman to purchase up to an aggregate of 50,000 common shares of the Company at an exercise price of $4.60 per Option Share, vesting over a period of three years and exercisable for five years from the date of grant.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC, and is in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility. Emerald has also entered into hemp chaff purchase agreements in 2018 and subsequent years. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; Emerald becoming a premiere provider of cannabis; and expansion of facilities.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labor; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!

Emerald Health Therapeutics Inc.

lockPrivate Group

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-to-sale enterprise, Emerald has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise. Our ambition is to be at t...

people5 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200 200  png
Request Membership


Emerald Health Therapeutics Inc.

lockPrivateGroup

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-t......

people5 Members       (0)

8020 Admin posted a press release Emerald Health Therapeutics Applauds Government of Canada for Proposing Amendment to Cannabis Excise Tax in Federal Budget in Emerald Health Therapeutics Inc.

VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) applauds the Government of Canada for proposing to amend the excise tax calculation for cannabis in the federal budget announced yesterday.


The implementation of the proposed revision announced in the federal budget would result in the calculation of the excise duty of ingestible cannabis and hemp products being based on the quantity of THC in the products, as opposed to the current tax set in relation to the product volume. Certain low-THC products would also be subject to lower excise duties, which would provide additional tax relief for cannabis products typically used by individuals for medical purposes. If implemented, the proposed changes are expected to come into effect on May 1, 2019. Emerald believes that these revisions are likely to improve its profit margins on the products it intends to produce from its contracts to acquire harvested hemp. As previously announced, Emerald has entered into contracts to purchase 500 acres of harvested hemp (which contains very low levels of THC) in 2018 and up to 1000 acres of harvested hemp per annum from 2019 to 2022.


“We believe that the federal government’s recommendation to revise the cannabis excise tax will reduce taxes on the low-THC products Emerald intends to produce from its contracted hemp harvest for medical use,” stated Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We expect that this proposed revision to the excise tax calculation will enhance our opportunity to utilize our purchased hemp in an economically viable way as feedstock for new cannabinoid-containing ingestible products.”


Emerald previously announced partnerships with industry leaders in extraction and technology to enhance biological activity, its filing of patent applications, and its goal to produce value-added cannabinoid-based products that provide consumers with consistent product characteristics. Emerald has already produced various high-CBD products and management believes it is well-positioned to produce additional high-CBD, low-THC value-added products from both cannabis and hemp.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) is a Canadian licensed producer of medical and adult use cannabis. It’s Pure Sunfarms 50% joint venture owns and operates a sophisticated 1.1 million square foot greenhouse cultivating high quality, low cost cannabis in the Lower Mainland. Its wholly owned subsidiary. Verdélite Sciences Inc. is in the process of completing a 75,000 square feet indoor facility near Montreal, Quebec. Both facilities are rapidly expanding their commercial production. Emerald has also secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres per annum from 2019 to 2022 with the goal of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, and large-scale agri-business and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include augmentation of capabilities; build out of the Verdalite facility; production capacity of various facilities; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counterparties to perform contractual obligations as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!

8020 Admin posted a press release Emerald Health Therapeutics Appoints Vice President, Communications and Stakeholder Relations in Emerald Health Therapeutics Inc.

Allan Rewak brings extensive experience with government, media, communications and public affairs


VICTORIA, British Columbia, March 18, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Allan Rewak has been appointed Vice President, Communications and Stakeholder Relations, effective April 15, 2019.


Prior to joining Emerald, Mr. Rewak was the Executive Director at the Cannabis Council of Canada (C3), Canada’s national industry association for cannabis, cultivators and processors. In the role, he unified multiple industry associations into one collective and navigated the sector through the successful legalisation of adult-use cannabis. For his work, the Financial Post named him “One of the 20 Power Players Setting Down Roots in the Cannabis Industry”.


Mr. Rewak also served as Director of Communications and Stakeholder Relations at Newstrike Resources, a partner at Pathway Group, and a consultant at Leonard Domino & Associates.


“We are pleased to welcome Allan to the Emerald team,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “His deep industry relationships and proven experience in the sector, combined with his strong background in communications and stakeholder relations with all major relevant sectors of the industry, are expected to augment our existing capabilities.”


Mr. Rewak has been granted an option to acquire up to 150,000 common shares vesting over a three-year period.


About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include augmentation of capabilities; build out of the Verdalite facility; production capacity of various facilities; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counterparties to perform contractual obligations as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!

8020 Admin posted a press release Emerald Health Therapeutics Continues to Grow Sales with First Cannabis Shipment to Ontario Cannabis Retail Corporation in Emerald Health Therapeutics Inc.

Ontario marks a key province to offer Emerald-branded cannabis products, expanding Emerald’s market opportunity to over half of the Canadian cannabis-consuming population


VICTORIA, British Columbia, March 14, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) has fulfilled its first purchase order of cannabis from Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”).


“As we scale up production in our wholly-owned, premium indoor growing facility, Verdélite, and our large-scale, state-of-the-art joint venture greenhouse operation, Pure Sunfarms, we are consistently meeting our supply commitments of Emerald-branded adult-use cannabis in British Columbia and Newfoundland Labrador, and we are now prepared to provide the same service to the Ontario Cannabis Retail Corporation and other provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We now have distribution access to over half of the Canadian population of adult-users of non-medical cannabis. We are advancing prospective supply agreements that we expect will ultimately give us nation-wide market exposure.”


Currently, Emerald’s cannabis supply is provided primarily through its 88,000 sq. ft. Verdélite indoor facility in Saint Eustache, Quebec, and through Pure Sunfarms, its 50%-owned 1.1 million sq. ft. greenhouse facility in Delta, British Columbia. It is working to expand sources and volume of indoor, greenhouse and outdoor-grown cannabis and cannabinoid products. In 2018, Emerald acquired 500 acres of harvested hemp and expects to purchase approximately 1,000 acres of harvested hemp in 2019. It is implementing steps intended to achieve large-scale extraction and softgel encapsulation of cannabis products.


Emerald-branded products are expected to be available through the OCS next week.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC has completed the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and expects to purchase approximately 1000 acres of harvested hemp in 2019 to 2022, to provide a low-cost source of cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

10 days

8020 Admin posted a press release Emerald Health Therapeutics Sees Pure Sunfarms Licensed for 1.03 Million Square Feet of Cannabis Cultivation; Full Planting Targeted for End of April in Emerald Health Therapeutics Inc.

Pure Sunfarms’ large-scale facility with 16 grow rooms is optimized for year-round production and expected to yield more than 80 harvests annually


VICTORIA, British Columbia, March 11, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), received from Health Canada its seventh amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 206,000 square feet of growing area in the fourth and final quadrant of the greenhouse brings Pure Sunfarms’ total licensed cannabis production area to approximately 1.03 million sq. ft. in 16 grow rooms. The newly licensed area is expected to be fully planted by the end of March.


“Pure Sunfarms is now licensed across all its growing areas and we congratulate their team for this significant accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “With Emerald’s 50% stake in one of the largest fully operational cannabis production facilities in the world, we expect to realize significant economic value from Pure Sunfarms. We expect our supply agreement with Pure Sunfarms for 40% of its 2019 production, along with our Quebec and hemp operations, to support strong quarter to quarter sales growth this year.”


Pure Sunfarms is now replanting Quadrant 1 of the greenhouse following the planned suspension of production in that area last autumn to begin the process of installing supplemental lighting to maximize yields in the winter months. This project is planned to be completed in Q3, when supplemental lighting will again be required. Pure Sunfarms expects Quadrant 1 to be fully replanted by the end of April 2019, at which time Pure Sunfarms will be in production in the entire 1.03 million square feet of cultivation space.


Last week, Pure Sunfarms announced a wholesale supply agreement with Canna Farms Ltd., which will offer a select variety of Pure Sunfarms-branded high-quality dried flower products to Canna Farms’ medical clients for retail purchase. This initiative is intended to help expand the marketing and sales reach of Pure Sunfarms' branded products.  


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC has a 1.1 million square foot (25 acre) greenhouse with 1.03 million square feet of licensed cannabis cultivation space in Delta, BC. Its Verdélite operation in Québec is completing the build-out of its 88,000 square foot indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and expects to purchase approximately 1,000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include planting schedules; future sales; realization of economic value; build out of the Verdelite facility; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

14 days

8020 Admin posted a press release Emerald Health Therapeutics' Licensed Endo Product Wins Taste For Life's 2019 Essentials Supplement Award in the U.S. in Emerald Health Therapeutics Inc.

Novel Emerald endocannabinoid-supporting products well-positioned to develop brand presence and market demand among both cannabis and non-cannabis users


SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner’s, (Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For Life’s 2019 Essentials Supplement Award, which recognizes the most outstanding natural supplements in health and wellness in the U.S. Emerald will launch the Endo product line in Canada in 2019 through its joint venture, Emerald Health Naturals (“EHN”), which secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (“ECS”), but which does not contain cannabis.


Endo Bliss is part of the Endo product line of novel nutritional supplements created to support the human ECS. Formulated to promote positive outlook and mood, Endo Bliss features Emerald’s proprietary PhytoCann® Complex, an herbal and botanical complex completely free of cannabis or its derivatives. Saffron extract, which has been proven to improve mood and outlook, is also included in the formula to further bolster its efficacy.


“Endo Bliss’ recognition as a top natural supplement to support endocannabinoid health by Taste for Life in the U.S. is a notable accolade,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “The Endo product line offers people who use natural health products a completely new and unique category of nutritional supplement. To receive this award, at a time when more US retailers are showing interest in putting Endo on their shelves, is added confirmation to us that Endo is fulfilling an unmet need in the marketplace for non-cannabis products that support the endocannabinoid system.


“We aim to launch the Endo line this year via an extensive nationwide retail network of Canadian retailers that will far exceed the current number of cannabis retail stores. We will not only create a unique profit opportunity with this product line, we will create significant incremental recognition for Emerald cannabis products and an entrenched presence in natural health food, pharmacy and other channels should non-psychoactive cannabis products be permitted in these channels in the future.”


The endocannabinoid system is a biological system critical in establishing and maintaining homeostasis in every cell, tissue and organ in the body. EHB harnessed the power of non-cannabis herbs and botanicals to offer a complete nutritional line of supplements that supports the endocannabinoid system to address consumers’ most common health concerns. In addition to Endo Bliss, Emerald’s lineup includes Endo Sleep, Endo Brain, Endo Calm and Endo Inflame for rejuvenating rest, enhanced cognition, stress and anxiety support, and pain and inflammation relief.


Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.com. EHN has not announced Canadian retailers.


About Taste For Life


Taste For Life aims to educate and motivate consumers to make informed purchasing decisions. Utilizing research and insights from industry experts, the magazine covers food and special diets, vitamins, minerals, supplements, herbs, homeopathy, natural food and beauty products, recipes and other products or modalities for overall wellness.


About The Endo Product Line*


Endo Brain - Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.


Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.


Endo Calm - Naturally addresses your body’s response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.


Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.


Endo Inflame - Naturally promotes your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.


* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 88,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

29 days

8020 Admin posted a press release Emerald Health Therapeutics Launches 88,000 Square Foot State-of-the-Art, Fully-Integrated Indoor Facility and Verdélite Brand in Québec in Emerald Health Therapeutics Inc.

Verdélite is an essential element of Emerald’s commitment to develop a unique product portfolio for the large Québec marketplace and other provinces, and aims to create approximately 140 jobs in Saint-Eustache


SAINT-EUSTACHE, Québec, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced the launch of Verdélite Sciences Inc. ("Verdélite"), a wholly-owned, Québec-based production subsidiary licensed by Health Canada. Formerly known as Agro-Biotech, Verdélite currently produces high-grade dried cannabis for medical and adult-use purposes.


Emerald is nearing completion of its over $100 million investment to secure and expand its multi-purpose facility to 88,000 square feet and enable the complete cycle of indoor cultivation, product development and automated packaging of cannabis products. Upon reaching full production levels in mid-2019, Verdélite projects it will have created approximately 140 jobs.


"This investment will enable us to produce quality cannabis products adhering to our high growing and processing standards,” said Thierry Schmidt, President of Verdélite Sciences. “Verdélite will be synonymous with differentiated and value-added cannabis products, and we are pleased to see the level of industry skill and enthusiasm coming from the Saint-Eustache community and the local interest and support to help contribute to our success.”


In addition to 23 state-of-the-art growing rooms, the facility will include an analytical testing laboratory as well as a research centre for product innovation and extraction technology. These capabilities will also position Verdélite to competitively participate in the development and production of edible cannabis products, which are expected to be sanctioned by Health Canada by October 17, 2019.


"We’re delighted to see our Québec-based Saint-Eustache facility coming online and adding to our capability to deliver high quality adult-use and medical cannabis products,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “The Verdélite team has been working tirelessly to bring to fruition one of the core assets in Emerald’s national and international development strategy.”


Emerald acquired Verdélite in May 2018 with an operating footprint of 25,000 square feet. The full 88,000 square foot facility is expected to be operational in Q2 2019, with approximately 50,000 square feet of cannabis flowering capacity in precision-controlled environments. Verdélite possesses approximately 200 strains of cannabis.


By the Numbers



  • 140 estimated full-time jobs in Saint-Eustache once fully operational

  • 88,000 square foot purpose-built cannabis production facility

  • 23 independent growing rooms

  • 200 cannabis strains

  • 12 processing and packaging rooms.


About Verdélite Sciences Inc.

Verdélite, a wholly owned subsidiary of Emerald Health Therapeutics, Inc., is a Health Canada- licensed cannabis cultivation facility located in Saint-Eustache, 30 km north of Montréal, Québec. This facility, purpose-built to produce, process and package cannabis products, is nearing completion of an expansion to 88,000 square feet. The facility has abundant access to high-quality low-cost water and electricity.


About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acres) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 88,000-square-foot indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres from 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agribusiness, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceuticals, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Verdélite/Emerald Investor and Public Relations
Marie-Eve Chaume
+1 514 951-5498
mechaume@Verdélite.ca


Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include projected job creation figures at our operating facilities; production and processing capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Announces Completion of Pure Sunfarms CAD$20 Million Credit Facility with Bank of Montreal and Farm Credit Canada in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.


“Pure Sunfarms is proud to enter into this Credit Facility with these two highly respected institutional lenders,” said Mandesh Dosanjh, President and Chief Executive Officer, Pure Sunfarms. “This is truly an exciting time for our organization and we are appreciative of the support of each as Pure Sunfarms establishes itself as a vertically integrated supplier to the Canadian cannabis market.”


“As Pure Sunfarms approaches operational positive cash flow, completion of a non-dilutive financing with these financial institutions is an excellent accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We look forward to Pure Sunfarms’ rapid quarterly growth through this year as it comes fully onstream.”


The Credit Facility, which matures on February 7, 2022, is secured by Pure Sunfarms’ greenhouse facility, and contains customary financial and restrictive covenants.


With conversion of all growing areas, totaling more than one million square feet, of its greenhouse facility completed, Pure Sunfarms expects to be in production in all quadrants of the facility in the first quarter of this year. The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms optimized for year-round harvesting (more than 80 harvests annually).


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


 

!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Announces Pure Sunfarms' Selection to Supply Ontario Cannabis Store in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.


“Pure Sunfarms’ supply agreement with the OCS – our first with a provincial government distributor – is a tremendous step forward for our organization, putting our branded quality products on the OCS website and soon retailers’ store shelves, and into the hands of our consumers,” said Mandesh Dosanjh, President and Chief Executive Officer, Pure Sunfarms. “The confidence of the OCS in Pure Sunfarms’ ability to reliably supply safe, consistent quality products is a testament to the hard work of the entire Pure Sunfarms team, which has been relentless in advancing our organization to this stage. We are thrilled to be working with the OCS in Canada’s most populated province and look forward to finalizing additional supplier agreements for other provinces and growing the Pure Sunfarms brand nationally.”


“Pure Sunfarms’ progress in building out an eminent cannabis growing facility, which provides a natural progression into retail sales and product development for the growing and evolving cannabis marketplace, as well as its accomplishment in winning its first provincial government supply agreement is a great validation of the broader business strategy. I applaud CEO Mandesh Dosanjh and the Pure Sunfarms team,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “With cannabis supply we have secured from Pure Sunfarms, our Verdélite operation, and other sources, Emerald has been supplying British Columbia and Newfoundland/Labrador under existing supply agreements and expects to imminently ship to Ontario under the supply agreement it announced last fall. The Pure Sunfarms operation is poised for significant value generation and is a vital part of Emerald’s portfolio.”


With this Ontario supply agreement in place, Pure Sunfarms can commence shipments to the OCS upon receipt of its packaging and processing licenses from Health Canada, which it continues to expect in the near term, subject to Health Canada’s own timelines.


Pure Sunfarms has been and continues to pursue additional supply agreements with other provincial government distributors and private retailers as it continues to sell directly to other Licensed Producers to capitalize on favorable spot market pricing amidst the continuing cannabis supply shortage across Canada.


Pure Sunfarms recently completed conversion of all of the growing area – more than 1 million square feet – at its 1.1 million square foot greenhouse in Delta, British Columbia, making it one of the largest single cannabis growing facilities in the world. The first three quadrants of this facility are licensed for cultivation, with the fourth quadrant currently under Health Canada licensing review. Pure Sunfarms expects to be in production in all four quadrants of this facility in the first quarter of 2019.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

1 month

8020 Admin posted a press release Emerald Health Therapeutics Secures Proprietary Extraction Technology and Extraction Capabilities in Agreement with Indena in Emerald Health Therapeutics Inc.

Emerald receives certain exclusive rights to established Phytosome® technology to enhance absorption and bioavailability of cannabinoid products

Leading global extraction researcher and manufacturer to provide license of technology and global industrial-scale manufacturing of non-psychotropic cannabinoids for food and health use in Canada

VICTORIA, British Columbia, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.


This collaboration leverages Indena’s decades-long global presence in the plant extraction industry and botanical experience in phytochemical research. Indena is the world’s leading company in the identification, development, and production of plant-derived active ingredients for the pharmaceutical, health food, and personal care industries. It is adapting an existing proprietary extraction process to facilitate hemp extraction and will exclusively provide Emerald in Canada with this highly optimized process for extracting and isolating CBD to manufacture cannabinoid-based products. With multiple international large-scale extraction facilities, Indena will be the exclusive  third party manufacturing supplier of CBD for Emerald. Emerald will use this CBD in its production of certain product lines.


Emerald and Indena have also established a research collaboration to assess the use of Indena’s Phytosome® technology in combination with various cannabinoids. The agreement provides Emerald with exclusive access to certain of Indena’s scientifically validated, commercially available Phytosome® formulations and plant-based technology that is designed to enhance solubility of compounds that are usually poorly absorbed by the body, such as cannabinoids.  For Emerald, evaluating and securing superior technologies like Phytosome® is an important aspect of its objective to develop differentiated and effective cannabinoid-based products to improve human health.


“Emerald is one of the few Licensed Producers in Canada focused on applying proprietary  innovation to improve the medical applications of cannabinoids, which is fully aligned with Indena’s scientific approach to phytochemical research,” said Stefano Togni, Business Development and Licensing Director of Indena. “We believe that both companies’ approaches to quality and innovation will create an exciting partnership that will add value to the industry and better serve patients and consumers who look for excellence in their products and predictive health outcomes.”


“In my many years as a practicing naturopathic physician, Indena has been the gold standard in plant extraction in the natural health products industry,” said Dr. Gaetano Morello, Chair of Emerald’s scientific advisory board and CEO of Emerald Health Naturals. “By gaining access to their technology, know-how, and expertise, Emerald is propelling itself as a leader in the innovation of next generation CBD-based products.”  


“Reinventing processes and replicating existing expertise does not make sense to us when we can work with the best. We welcome Indena’s decision to work closely with our team,” added Dr. Avtar Dhillon, President and Executive Chairman of Emerald Health Therapeutics. “We aim to bring together unbeatable global expertise, technology and infrastructure to innovate and commercialize value-added cannabinoid-based products, and we will do this with both internal resources and industry-leading partners.


“Indena is one of the oldest and most established extraction businesses in the world. They have served international pharmaceutical companies with natural anti-cancer ingredients. They are leaders in nutraceutical products. With multiple extraction-related deals announced, our comprehensive and cohesive international strategy for cannabis and hemp extraction is unfolding. We look forward to impactful cannabinoid product development advancements in 2019.”


About Indena


Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants for use in the pharmaceutical, health food and personal care industries. Backed up by almost a century of botanical experience, the company holds more than 120 primary patents, has published more than 700 scientific studies and co-operates with the world’s most prestigious universities and private research institutions. Indena employs about 800 staff, investing around 10% of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has 5 production sites and 5 international branches throughout the world and manages sales in more than 70 countries. The Company’s experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMA, FDA and ESCOP, and cooperate on the update of all the main pharmacopoeias. Today, Indena also supplies capacity and expertise for custom manufacturing services and related key technologies. In particular, the company has expanded its offering with a new kilolab to handle semisynthetic and totally synthetic active pharmaceutical ingredients (API) that require high containment, ie. occupational exposure limit (OEL) of 20 μg/m3.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build-out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries. 


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Discharge of Litigation in Emerald Health Therapeutics Inc.

VANCOUVER, British Columbia, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.


Pursuant to the settlement, all claims against Verdélite have been discharged without Verdélite making any payment or providing any compensation to Pivot.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; increased commercial production; implementation of future business plans; intellectual property and product development; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics' Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US in Emerald Health Therapeutics Inc.

Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada


VICTORIA, British Columbia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019.  The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.


In December 2018, EHT received natural product numbers (NPNs) from Health Canada to sell Endo in Canada. EHN is owned 51% by Emerald and 49% by EHB.


“For the Endo products to be embraced by retailers with such high standards of retail excellence and broad reach like Whole Foods Market in the US is an important milestone for this unique natural health supplement line,” said Gaetano Morello, ND, CEO of Emerald Health Naturals. “A non-cannabis product line capable of nurturing the endocannabinoid system is a unique product category - and it is one that is garnering significant attention in the US. We aim to similarly build strong distribution channels with top retailers in Canada in 2019.”


“With 60% of cannabis users also being users of natural health products, we have a two-pronged opportunity in Canada to build a stand-alone market for the Endo product line for cannabis non-users as well as achieve Emerald brand recognition among cannabis users in channels unable to carry cannabis products,” said Avtar Dhillon, President and Executive Chairman, Emerald Health Therapeutics. “Natural health product stores, pharmacies, and even grocery stores may all be potential outlets for the Endo product line. We look forward to offering the proprietary Endo products to Canadian consumers this year.”


Endo nutritional supplements feature PhytoCann-Complex™, a proprietary formulation consisting of non-cannabis, non-psychoactive, plant-based bioactive compounds that support the body’s endocannabinoid system. The role of the ECS as the body’s innate balancing mechanism is key to the regulation of everything from appetite, energy, metabolism, fertility and immunity to sleep, mood, pain perception and memory.  The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss and Endo Inflame, and they are intended to naturally address the body’s response to conditions such as stress, anxiety, restless sleep and pain, and foster overall health and wellness.


Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.com.


About The Endo Product Line*

Endo Brain -
Naturally supports mental acuity and cognition by nurturing and nourishing your endocannabinoid system.


Endo Sleep - Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.


Endo Calm - Naturally address your body’s response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.


Endo Bliss - Naturally supports a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.

Endo Inflame - Naturally promote your body’s healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.

* The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health sees Expansion of Pure Sunfarms' Cannabis Cultivation License to 825,000 Square Feet in Emerald Health Therapeutics Inc.

1.1 million square foot Pure Sunfarms facility on track to reach full production capacity in first half 2019


VICTORIA, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.


Pure Sunfarms has also completed conversion of the approximately 206,000 square feet of growing area in the fourth and final quadrant, which is under review by Health Canada with respect to further amendment of Pure Sunfarms’ cultivation license. This further amendment would expand its permitted production area to just over 1.03 million square feet. The remaining approximately 69,000 square feet of the facility is being converted to processing and extraction activities. The Pure Sunfarms Delta greenhouse will be one of the single largest cannabis growing facilities in the world.


“With deep cannabis and large-scale greenhouse growing expertise, established operational systems, and cannabis strains well-suited to a greenhouse environment, we expect Pure Sunfarms’ leadership in optimized greenhouse cannabis growing to achieve attractive quality, yield, and profitability,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “We expect this facility to be in full production in the first half of 2019. With Emerald’s supply agreement for 40% of Pure Sunfarms’ 2019 production along with our Quebec and hemp operations, we are strongly positioned for quarter to quarter sales growth.”


All supplemental lighting is operational in Quadrants 2 and 3 of the Pure Sunfarms facility, and is expected to be operational in Quadrant 4 upon start of production, supporting maximum yields during the lower daylight winter months. Supplemental lighting infrastructure is currently being installed in Quadrant 1 and will be completed prior to Quadrant 1 resuming production in late February 2019. Conversion of Quadrant 1 was completed in April 2018 without supplemental lighting to enable immediate production during the summer when supplemental lighting was not needed.


The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms (13 of which are now licensed) optimized for year-round harvesting (more than 80 harvests annually).


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square foot (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite operation in Québec is completing the build out of its 75,000 square feet indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Secondary Offering in Emerald Health Therapeutics Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.


The Selling Shareholder will receive all of the net proceeds from the Secondary Offering. No securities are being sold by the Company.


In connection with the Secondary Offering, the Company has agreed to file a shelf prospectus supplement qualifying the Secondary Shares for distribution in each of the provinces of Canada, except Quebec, in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.


The closing date of the Secondary Offering is expected to be on or about January 16, 2019, and is subject to customary closing conditions.


This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdélite (previously called Agro-Biotech) operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include statements relating to the filing and effectiveness of the prospectus supplement; the anticipated closing date of the Secondary Offering; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to meet the conditions of closing of the Secondary Offering; filing of the shelf prospectus supplement; uncertainty with respect to the completion of the Secondary Offering; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

2 months

8020 Admin posted a press release Joint venture to distribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).


Emerald has invested $5,000,000 for 51% equity ownership of EHN. EHB has granted EHN the exclusive Canadian distribution rights to EHB’s award-winning product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.


Market research commissioned by the Company identified that approximately 60% of legal cannabis users also use natural health products. This strong consumer overlap between the two markets is expected to create a unique opportunity for Emerald to build its health brand through EHN and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not authorized to sell cannabis under the Canadian federal cannabis regulations for recreational use which came into force on October 17, 2018. However, if these channels are approved in the future, the Company expects to be well positioned to introduce its cannabis-based products into these channels.


The formation of the Joint Venture is a “related-party transaction” as such term is defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as EHB is approximately 71% owned by Emerald Health Sciences Inc., which is also the holder of approximately 30.6% of the outstanding common shares of the Company. The Company is relying on the exemption from the formal valuation requirements of MI 61-101 set out in Section 5.5(b) of MI 61-101 and the exemption from the minority shareholder approval requirements of MI 61-101 set out in Section 5.7(a) of MI 61-101 in respect to the creation of the Joint Venture.


In connection with the formation of the Joint Venture, EHN has also acquired the assets of GAB Innovations (“GAB”) and has granted non-exclusive sub-distribution rights to Avricore Pharmaceuticals Inc. (formerly VANC Pharmaceuticals Inc.) (“Avricore”). Both GAB and Avricore have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN.


Emerald also announces that Chris Wagner has resigned as a director of the Company. As previously announced, Mr. Wagner stepped down as CEO effective November 28, 2018. Mr. Wagner will continue to act as a consultant to Emerald and provide assistance when needed.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include the operations of the joint venture; establishment of brands; sale of products; regulation of the cannabis industry; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; and receipt of hemp deliveries.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

3 months

8020 Admin posted a press release Weather Telematics Inc. to Exhibit at CES 2019 in Las Vegas in Emerald Health Therapeutics Inc.

TORONTO and OTTAWA, Ontario, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Internet of Things Inc. (TSX VENTURE: ITT; OTC: INOTF; FRANKFURT: 71T) (“IoT Inc.” or the “Company”) a strategic investor and operator of emerging technology companies with innovative IoT, AI and Blockchain solutions, is pleased to announce that its wholly-owned subsidiary, Weather Telematics Inc. (“WTX Inc.” or “Weather Telematics”) will be showcasing its innovative road safety data and smart mobility technology at the Consumer Electronics Show 2019 (“CES”) in Las Vegas from January 8th – 11th in the Canadian Delegation Booth (#1021, Tech East, Westgate).


Attendees that visit the booth will have the opportunity to interact with the Weather Telematics’ dynamic platform that mitigates weather risk, reduces traffic congestion and makes connected and autonomous navigation safer in all types of road conditions. Throughout the conference, Weather Telematics will be hosting a technology presentation at its booth focused on its smart mobility solutions for autonomous driving and connected vehicles.


From tech powerhouses to innovative start-ups, companies big and small from all industries come to CES to introduce the latest innovation to the global market. Exhibitors feature products from all facets of tech, including sports and vehicle technology, artificial intelligence, drones, augmented and virtual reality, smart cities and resiliency, digital health and more. Manufacturers, developers and suppliers gather at CES to not only showcase game-changing technology to the world, but to also build strong business relationships with new and existing industries.


“Our roots lie in designing and deploying the largest meteorologically approved mobile weather observation platform in North America. Since 2010, this network has delivered millions of observations daily to the National Weather Service allowing for delivery of dynamic road weather conditions across the USA,” says Michael Keefe, Chief Strategy Officer at Weather Telematics. “We are honoured to be selected as one of the leading information and communications technologies companies within Canada and to be featured within the Canadian Delegation booth at CES.”


For OEMs, suppliers and tech companies in the smart mobility space wishing to learn more about partnering with Weather Telematics and discussing integration opportunities for Weather Telematics’ software and sensors into their products or technologies, visit www.weathertelematics.com or visit the booth during CES to schedule a private meeting.


About Weather Telematics Inc.
Founded in 2010, Weather Telematics Inc. is a Canadian-based, IoT data science company offering road safety data products for industrial, government and consumer markets. Weather Telematics uses a proprietary vehicle-mounted mobile IoT sensor network and AI machine learning system to generate real-time and predictive road weather conditions, road hazard risk alert notifications and dynamic routing applications. The Weather Telematics platform mitigates weather risk, reduces traffic congestion and makes connected and autonomous navigation safer in all types of road conditions.


To learn more, visit: www.weathertelematics.com
Follow Weather Telematics on Twitter: https://twitter.com/weathertx


About Internet of Things Inc.
Internet of Things Inc. is a strategic investor and operator of emerging technology companies with innovative technology solutions. The Company creates value through its portfolio companies’ expertise in IoT, AI and Blockchain solutions, by turning data into actionable intelligence to drive more efficiency into organizations.

The Company owns Weather Telematics Inc., has a joint venture partnership, New Hope IoT Intl Inc., with New Hope Data Technology Co. Ltd., and has its headquarters in Toronto, Canada. 

Follow Internet of Things Inc. on:

















Facebook: https://www.facebook.com/InternetofThingsInc/
Twitter: https://twitter.com/iotintl
LinkedIn: https://www.linkedin.com/company/internet-of-things-inc-

For further information, contact:


Internet of Things Inc. 
Kim Nguyen, Director of Corporate Communications
Mobile: (647) 201-7993
Email: knguyen@iotintl.com
To learn more, visit: www.iotintl.com


Weather Telematics Inc.
Michael Keefe, Chief Strategy Officer
Mobile: (416) 580-6559
Email: mkeefe@weathertelematics.com
To learn more, visit: www.weathertelematics.com


Cautionary and Forward-Looking Statements
Statements contained in this news release, which are not historical facts, are forward-looking statements that involve risk, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements included in this news release are based on information available to the Company on the date hereof. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results of the Company to differ materially from the conclusion, forecast or projection stated in such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to factors referenced in the Company’s other continuous disclosure filings, which are available at sedar.com. Readers should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking statements, except as required by applicable securities laws.


NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

!
Thumb 8020 monitor 200 200  png

8020 Admin

3 months

8020 Admin posted a press release Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada in Emerald Health Therapeutics Inc.

1.1 million square foot Pure Sunfarms facility steadily ramps capacity and production with industry-leading quality and yields in line with expectations


VICTORIA, British Columbia, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.


“Pure Sunfarms is already one of the largest licensed cannabis production facilities in the industry, and we expect completion of the conversion in Q1,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “With deep cannabis and large-scale greenhouse-growing expertise, established operational systems, and multiple cannabis strains being grown, Pure Sunfarms is achieving industry-leading quality and yields in line with our expectations. We expect this facility to be in full production in the first half of 2019, and aim for it to be one of the best cannabis production operations in the industry.


“Pure Sunfarms has delivered to Emerald contracted cannabis shipments that we are selling under the Emerald brand. It is also selling to other LPs, with favourable spot market pricing, as it awaits its packaging sales license to commence direct sales to provincial distributors. Pure Sunfarms continues to implement its plan to be a vertically integrated cannabis producer and marketer.”


Pure Sunfarms has completed conversion of the remainder of Quadrant 3 and is awaiting Health Canada approval for this additional approximately 138,000 square feet of production area. Pure Sunfarms expects to complete conversion of Quadrant 4 (approximately 275,000 square feet) by year end and anticipates Health Canada approval of that additional area by the end of January 2019. At a total licensed area of 1.1 million square feet, Pure Sunfarms’ Delta greenhouse will be one of the single largest cannabis growing facilities in the world.


All supplemental lighting is operational in Quadrants 2 and 3, and is expected to be operational in Quadrant 4 upon start of production, supporting maximum yields during the lower-daylight winter months. Supplemental lighting will be installed in Quadrant 1, which was completed as per plan earlier this year without supplemental lighting in order to permit immediate production during the summer months when supplemental lighting is not required. Quadrant 1 is expected to resume production by the end of February 2019.


The technologically-advanced Delta 3 greenhouse design is based on decades of large-scale, low-cost agricultural production experience and extensive cannabis expertise, resulting in a state-of-the-art facility with 16 grow rooms (eleven now licensed) optimized for year-round harvesting with more than 80 harvests annually.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Québec is completing its 75,000 square feet indoor facility. Commercial production is expanding in both facilities. In addition, Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


 


!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System in Emerald Health Therapeutics Inc.

Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health

Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product line

VICTORIA, British Columbia, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. ("Emerald" or “the Company”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients. EHN intends to launch the Endo product line over-the-counter in Canadian natural health product, grocery, and pharmacy stores by mid-2019.


“Our Endo product line was developed by internationally recognized natural health product experts and is unique in the natural healthcare marketplace. We are very excited to be able to offer our Endo products to Canadian consumers to support their endocannabinoid systems and improve aspects of their health,” said Dr. Gaetano Morello, CEO of EHN. “We are leveraging our key strategic relationships and working hard on the marketing, manufacturing and logistical steps in order to launch the Endo line by mid-2019.”


The Endo product line was developed by Emerald’s joint venture partner, San Diego-based Emerald Health Bioceuticals, Inc. (“EHB”), and its scientific advisors. Over the last year, EHB has secured multiple distribution and sales channels in the United States and internationally for the Endo product line, ranging from small independent natural health product retailers to nation-wide grocery store chains and Amazon.com. EHN, which is owned 51% by Emerald and 49% by EHB, will have exclusive Canadian distribution rights to the Endo products.


These cannabis-free nutritional supplements feature PhytoCann-Complex™, a proprietary formulation designed to support the body’s endocannabinoid system, which plays a central role in the orchestration, maintenance, and balance of health and well-being. The products include Endo SleepTM, Endo InflameTM, Endo BrainTM, Endo BlissTM, and Endo CalmTM. Endo Brain was recently awarded a prestigious 2018 SupplySide Consumer Packaged Goods Editor’s Choice Award for Brain Health, building on its NEXTY "Editor's Choice" Best New Supplement Award in the natural products industry in 2017.


“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “In the event that CBD and other non-psychoactive cannabinoid products are allowed to be sold in these channels in the future, Emerald will be well positioned to add its cannabinoid compounds to the Endo product line and leverage its early marketing advantage. Emerald’s vision is to enhance human health through cannabis science. The creation of EHN and the launch of the Endo product line in Canada are key steps in Emerald’s strategy to achieve this goal.”


As announced in the Company’s press release dated November 22, 2018, the Company has obtained conditional approval of the TSX Venture Exchange for the formation of the EHN joint venture. The parties are in the process of finalizing definitive documentation with respect to EHN. Formation of EHN is conditional upon final regulatory approval and settlement of definitive documentation.


About the Endocannabinoid System


The endocannabinoid system (“ECS”) is a biological system with a vital role in regulating human health and disease. A lack of balance in the endocannabinoid system is likely to have adverse consequences in a number of human health conditions. The ECS is activated by endocannabinoids produced naturally in the body, but also by cannabis or non-cannabis plant ingredients that mimic the actions of cannabinoids produced in the body. All products in the Endo product line contain Phyto-CannTM Complex, which has been formulated by leading nutritional and cannabinoid scientists with non-cannabis herbal and botanical cannabinoids designed to favorably impact the ECS.


About Emerald Health Therapeutics


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing the conversion of its 1.1 million square feet (25 acres) greenhouse in the Lower Mainland to cultivate cannabis and its Agro-Biotech operation in Québec is currently operating out of its 75,000 square feet indoor cannabis cultivation facility. Commercial production is expanding in both facilities. In addition, Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol out of its hemp harvest. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald, EHN and EHB are all part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include completion of the joint venture and obtaining exclusive Canadian distribution rights; establishing a brand; launch of the Endo line in 2019; sales of non-cannabis products; development of sales channels; expansion of permitted sales of cannabis; leveraging of distribution channels; development of new products; the benefits and effects of certain products; production capacity of various facilities; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain necessary financing; failure to settle final documentation; failure to obtain regulatory approvals; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law. 

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale in Emerald Health Therapeutics Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VICTORIA, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.


The Company intends to use the net proceeds of the Offering to fund the completion of capital projects, research and development, working capital, and general corporate purposes.


The Common Shares will be qualified under a shelf prospectus supplement to be filed by Emerald in each of the provinces of Canada, except Quebec, prior to closing in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.


The closing date of the Offering is expected to be on or about December 7, 2018, and is subject to certain conditions including, but not limited to, the Lead Investor being satisfied with the results of its due diligence, no material adverse change in the affairs of the Company, and the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.


This press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit http://www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include statements relating to the filing and effectiveness of the prospectus supplement; the use of proceeds from the Offering; the anticipated closing date of the Offering; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to meet the conditions of closing of the Offering; uncertainty with respect to the completion of the Offering; filing of the shelf prospectus supplement; the ability to obtain applicable regulatory approval for the Offering; failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin posted an update in EMERALD HEALTH THERAPEUTICS INC.

4 months

Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update

https://quotemedia.com/portal/quote/?qm_symbol=EMH%3ACC

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO.


“Emerald’s board of directors thanks Chris for his numerous contributions during this period of rapid growth and wishes him well in his future endeavours,” said Jim Heppell, a director of Emerald. “Emerald has now laid the groundwork for very rapid future growth. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations. Under his experienced stewardship, we expect Emerald to rapidly advance its differentiated business plan.”


Dr. Avtar Dhillon said, “Our plan is to build on the momentum of, and accelerate, our foray into the world cannabis arena and leverage our asset base to maximize our opportunities not only in Canada, but globally.  Our goal is to be a preeminent player on the global stage, with science-backed innovative cannabinoid products. As such, we are finalizing our expansive relationship with the Factors Group, which, when complete, is expected to provide industrial-scale extraction, encapsulation, packaging, and distribution capability. We intend to feed this processing capability with supply from our Pure Sunfarms joint venture, our Quebec facility, and hemp to be obtained through our supply agreement.”


Dr. Dhillon is a life sciences entrepreneur with more than 35 years of experience. He is CEO of Emerald Health Sciences, a major shareholder of the Company, and serves as a board member and chairman of several life science companies. He is also Chairman of the Cannabis Canada Council. As a founder/co-founder of many life science companies, he has raised more than $1B in public and private financings. As President and CEO of Inovio Pharmaceuticals, Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.). Prior to his business career, Dr. Dhillon practiced family medicine. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.


Emerald would also like to announce the departure of Paul Dillman as Executive Vice President of Global Sales and Marketing of the Company, effective as of November 22, 2018.  The board also thanks Mr. Dillman for his service.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; completion of the strategic relationship with Factors Group; implementation of future business plans; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Appoints Agro-Biotech President in Emerald Health Therapeutics Inc.

Thierry Schmidt brings extensive marketing and business strategy experience from consumer goods industry



VICTORIA, British Columbia, Nov. 22, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been appointed President of Agro-Biotech, its Québec-based licensed cannabis production operation, effective November 26, 2018. Mr. Schmidt brings 20 years of experience in marketing, brand advocacy, and general management; he has held senior leadership positions at Next Level Energy Inc., L’Oréal Canada, and British American Tobacco.


“We welcome Thierry to Agro-Biotech. As a born-and-raised Francophone with deep consumer goods business and marketing expertise, Thierry is ideally positioned to advance Agro-Biotech’s strategy to serve patients and consumers in Quebec,” said Mr. Chris Wagner, CEO, Emerald Health Therapeutics.


“Agro-Biotech and Emerald stand out in the cannabis industry for their extensive experience in life sciences as well as cannabis cultivation and marketing,” said Mr. Schmidt. “I look forward to driving a highly competitive production and product strategy for Agro-Biotech.”


Mr. Schmidt is a seasoned marketing executive leader with extensive experience in the consumer goods industry. He has held leadership and senior management positions in new business development, operations, sales, investor relations, and brand/consumer development. As General Manager at L’Oréal and Chief Marketing Officer at Next Level Energy Inc., he managed product development focused on developing a sustainable and profitable business model as well as brand advocacy. Furthermore, in his Business Development and Sales Director roles at British American Tobacco, he successfully developed and launched a national trade marketing strategy. 


Mr. Schmidt has been granted an option to acquire up to 125,000 common shares vesting over three years.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. It secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include production capacity of various facilities; expansion of facilities; implementation of business strategies; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.


!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture in Emerald Health Therapeutics Inc.

Joint venture to distribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies


VICTORIA, British Columbia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”).


The Company will invest $5,000,000 for 51% equity ownership of EHN. EHB will grant EHN the exclusive Canadian distribution rights to EHB’s award-winning product line in exchange for 49% equity ownership of EHN. EHB’s product line consists of nutritional supplements, which use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.


Market research commissioned by the Company identified that approximately 60% of legal cannabis users also use natural health products. This strong consumer overlap between the two markets creates a unique opportunity for the Company to establish its health brand through EHN and begin sales of endocannabinoid-supporting products in natural health product channels. These channels are not authorized to sell cannabis under the Canadian federal cannabis regulations for recreational use which came into force on October 17, 2018. However, if these channels are approved in the future, the Company expects to be well positioned to introduce its cannabis-based products into these channels.


The formation of the Joint Venture is a “related-party transaction” as such term is defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as EHB is approximately 71% owned by Emerald Health Sciences Inc., which is also the holder of 32% of the outstanding common shares of the Company. The Company is relying on the exemption from the formal valuation requirements of MI 61-101 set out in Section 5.5(b) of MI 61-101 and the exemption from the minority shareholder approval requirements of MI 61-101 set out in Section 5.7(a) of MI 61-101 in respect to the creation of the Joint Venture.


The parties are in the process of finalizing definitive documentation with respect to the Joint Venture. Formation of the Joint Venture is conditional upon final regulatory approval and settlement of the definitive documentation.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:


Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include final closing of the joint venture; production capacity of various facilities; expansion of facilities; increased commercial production; anticipated production costs; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

4 months

8020 Admin posted a press release Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments in Emerald Health Therapeutics Inc.

Emerald delivers first shipments to British Columbia and Newfoundland and Labrador


VICTORIA, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.


“It has always been important to us to ensure we fulfill the supply commitments we made to our provincial cannabis distribution customers. We are pleased that our initial deliveries have met this obligation and that we have the ability to provide consistent and increasing contracted shipments of Emerald products,” said Paul Dillman, Emerald’s Executive VP, Global Sales & Marketing. “With proprietary market research, differentiated products based on unique plant genetics, a recognizable, trusted brand, significant marketing expertise and bandwidth, and a growing sales team across Canada, we are aiming for a significant ramp-up in sales every quarter from these initial deliveries forward.”


“Emerald aims to assure its customers a secure supply of an array of products by establishing significant, diverse sources of indoor, greenhouse, and outdoor-grown cannabis and cannabinoid products. We have a strong and building foundation to achieve this goal,” said Chris Wagner, CEO at Emerald. “Our products are now available in stores and online in BC as well as Newfoundland and Labrador. Emerald is in negotiations with cannabis distribution authorities in several provinces as we continue to scale our production and sourcing efforts.”


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Portions of both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include ramping up production and sourcing of cannabis and cannabinoid products; future deliveries of Emerald products; availability of Emerald products in other provinces; production capacity of various facilities; expansion of facilities; anticipated production costs; and receipt of hemp deliveries.


Actual results may vary from forward-looking statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose(TM) Cannabis Products in Emerald Health Therapeutics Inc.

Unique Emerald cannabinoid formulations and dosage forms focused on providing consumers precise and differentiated products based on protected intellectual property


VICTORIA, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose™ cannabis products will, when made available to the public, provide consumers with products currently not available.


The seventeen Defined Dose™ cannabis patent applications relate to:



  • Inhaled dosage forms for smoking

  • Inhaled dosage forms for vaping; and

  • Capsule and edible formulations and dosage forms based on a novel understanding of cannabinoid molecular pathways and how they influence disease mechanisms.


Certain of the Defined Dose™ cannabis products are eligible for launch in Canada under existing Canadian regulations. Others are expected to be eligible under anticipated regulatory changes in 2019.


“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald’s filing of these patent applications is an important step,” said Chris Wagner, CEO of Emerald. “Our expanding research and development effort is focused on internal facilities and staff as well as forming key relationships with other cannabis research experts, such as our recently announced agreement with VivaCell Biotechologies Espana.”


“Emerald’s intent is to be at the forefront of understanding the mechanism of action of the endocannabinoid system and developing proprietary products that enable both medical and adult-use consumers to achieve measured outcomes with well characterized, reliable products,” said Avtar Dhillion MD, Executive Chairman of Emerald. “Our aim is to produce a product pipeline of next-wave cannabis products that fit the better-defined needs and preferences of consumers as Canada and other countries that legalize medical and recreational cannabis use.”


Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most important "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 member countries worldwide over the coming year.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Its 50%-owned Pure Sunfarms in BC is completing a sophisticated 1.1 million square feet greenhouse; its Agro-Biotech operation in Québec is completing a 75,000 square feet indoor facility. Both facilities are in commercial production. It has also contracted for approximately 500 acres of hemp harvest in 2018 and 1000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis in Canada and other countries; eligibility of products for launch in Canada; availability of products to the public; regulatory changes; potential for market growth; safety enhancement; expansion of research and development; future product development; future filings for patent protection; acceptance of filings; grant of patent rights; production capacity of various facilities; and expansion of facilities; and anticipated production costs.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals, including approval of patent filings; efficacy of safety features; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!
Thumb 8020 monitor 200 200  png

8020 Admin

5 months

8020 Admin posted a press release Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing in Emerald Health Therapeutics Inc.

VICTORIA, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. Mr. Dillman previously served as Vice President of Sales and Marketing, and will now be responsible for leading international marketing, sales, and customer services for Emerald as the company prepares to participate in the new legal cannabis landscape.  


“Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald. “With our branding, marketing and sales strategy, Emerald is poised to be a premiere provider of cannabis for medical and adult-use consumers. Paul’s marketing expertise has been invaluable to our team over the past few months, and we look forward to positioning Emerald to be a leader in Canada as well as the global cannabis industry.”


Mr. Dillman has three decades of experience in global marketing, sales, and general management and prior to Emerald, held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods. Mr. Dillman earned a bachelor of science from West Point (United States Military Academy) and a master of science in systems management from the University of Southern California.


The Company has granted 50,000 stock options to Mr. Dillman to purchase up to an aggregate of 50,000 common shares of the Company at an exercise price of $4.60 per Option Share, vesting over a period of three years and exercisable for five years from the date of grant.


About Emerald Health Therapeutics, Inc.


Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC, and is in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility. Emerald has also entered into hemp chaff purchase agreements in 2018 and subsequent years. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.


Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5


Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; Emerald becoming a premiere provider of cannabis; and expansion of facilities.


We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labor; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

!